{"commentary":{"count":23,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"youtube":8,"podcast":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05568095\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"STAR-221","nct_id":"NCT05568095","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=star-221-nct05568095. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"STAR-221","arms":[{"description":"Participants in this arm will receive Domvanalimab and zimberelimab doses once every 4 weeks (Q4W) in addition to chemotherapy with FOLFOX (oxaliplatin, leucovorin, fluorouracil) once every 2 weeks (Q2W) or Domvanalimab and zimberelimab once every 3 weeks (Q3W) in addition to chemotherapy with CAPOX (capecitabine and oxaliplatin) Q3W.","label":"Domvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)","type":"EXPERIMENTAL"},{"description":"Participants in this arm will receive Nivolumab Q2W and FOLFOX Q2W or Nivolumab Q3W + CAPOX Q3W.","label":"Nivolumab + FOLFOX/CAPOX (PI Choice)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Gilead Sciences","Taiho Pharmaceutical Co., Ltd."],"completion_date":{"date":"2026-08-28","type":"ACTUAL"},"conditions":["Advanced Upper Gastrointestinal Tract Adenocarcinoma"],"enrollment":{"count":1040,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Domvanalimab","type":"DRUG"},{"name":"Zimberelimab","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Leucovorin","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Nivolumab","type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"Arcus Biosciences, Inc.","official_title":"A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From date of randomization until date of death from any cause (Approximately 15 months)]"}],"references":[{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"}],"start_date":{"date":"2022-11-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","url":"https://clinicaltrials.gov/study/NCT05568095"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/star-221-nct05568095"}